What is the difference between CJC-1295 with and without DAC?

One chemical group. The DAC (drug affinity complex) version has an MPA-Lys unit added at the C-terminus that binds serum albumin, extending the measured human half-life to 5.8–8.1 days. Without it, the molecule is Modified GRF(1-29) and clears in well under an hour. Only the DAC version has a published human study.

Is there a CJC-1295 DAC dosing schedule?

Not one that can be cited, because no regulator anywhere has approved CJC-1295 and the FDA's Pharmacy Compounding Advisory Committee voted against it in December 2024 for lack of evidence of effectiveness. The only published human doses come from one 2006 study, which gave healthy adults 30 or 60 µg/kg subcutaneously — single ascending doses, then two or three doses given weekly or every two weeks. That is a trial protocol from a single dose-ranging study, not a schedule anyone recommends, and reproducing it as one would be inventing an authority that does not exist. The half-life is the reason people ask: at 5.8 to 8.1 days for the DAC version, a dosing interval is not a free choice.

How many units is 100 mcg of CJC-1295?

Four, in the vial this page loads by default — and four units is the problem, not the answer. 5 mg with 2 mL of bacteriostatic water is 2.5 mg/mL, which is 2,500 mcg/mL, so 100 mcg is 0.04 mL: four marks on a U-100 barrel, where a one-mark misread is a 25% error. Less peptide per millilitre moves the same dose further up the barrel and makes it readable: a 2 mg vial with 2 mL of water is 1 mg/mL, which puts 100 mcg at 10 units. You cannot fix it by pouring in more water indefinitely — most vials physically hold about 3 mL — which is exactly the case the calculator's “I want N units” mode exists for.

CJC-1295 Dosage Calculator — DAC and No-DAC

Synthetic 29-amino-acid GHRH analogue. One published human study from 2006; the FDA's advisory committee voted against it in 2024 for lack of effectiveness evidence.

Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.

Not approved

Not approved; advisory committee voted against it

Added to 503A Category 2 on 29 September 2023. On 4 December 2024 the Pharmacy Compounding Advisory Committee reviewed CJC-1295 for growth hormone deficiency and voted against adding it to the 503A bulks list, citing lack of evidence of effectiveness. It was removed from Category 2 on 22 April 2026 when nominations were withdrawn, and was not among the peptides reconsidered in July 2026. It is on no FDA list.

No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.

Anti-doping: Prohibited at all times. WADA class S2.1 — growth hormone releasing hormone and its analogues.

Calculator inputs

Set up your vial

Enter the label, dilution and dose. The result updates as you type.

Syringe volume

CJC-1295 in the vial

Vials sold online are commonly 2–10 mg

Bacteriostatic water to add

Dose per injection

No approved human dose exists for this compound. The dose shown is only a calculator input, not a recommendation or starting point.

More optionsReverse calculation, schedule and cost

Enter the bacteriostatic water you added and get the volume to draw.

Injections per week

Discard afterdays

Vial priceoptional

Draw to

4units(0.04 mL)

Concentration: 2500 mcg/mL
Water added: 2 mL
Doses in vial: 50

How the concentration is calculated

This divides the peptide by the water you add. The powder occupies a little volume of its own, which is negligible on a typical vial but not on one with a heavy bulking agent. When a product label states a concentration, use the label’s number.

A 4-unit draw is very small. Adding more water raises the volume and makes the dose easier to measure accurately.

Key facts

Molecular weight: 3,647.2 DaThat is CJC-1295 with DAC. Without DAC (Modified GRF(1-29)) it is 3367.97 Da. The DAC version carries an extra MPA-Lys unit that binds serum albumin — that single change is the entire difference between a roughly 30-minute and a roughly 7-day half-life.
Half-life: 5.8–8.1 days with DAC (measured in humans). The commonly quoted ~30 minutes for the no-DAC version has no primary human pharmacokinetic paper behind it.
Also sold as: Modified GRF(1-29), CJC-1295 DAC, tetrasubstituted GRF

Doses used in published studies

These are reproduced for reference. They are not recommendations, and an animal dose in mg/kg does not convert to a human dose.

humansubcutaneous

30 or 60 µg/kg

Teichman et al. 2006, healthy adults, ascending single doses then two or three weekly or biweekly doses. Produced a dose-dependent 2–10 fold rise in mean plasma growth hormone for at least 6 days and a 1.5–3 fold rise in IGF-1 for 9–11 days. The authors described these doses as safe and relatively well tolerated. This is CJC-1295 with DAC.

How good is the evidence?

One real published human study, from 2006, showing it raises growth hormone and IGF-1. Nothing since: no published human trial of any clinical outcome, and an FDA advisory committee rejection in December 2024.

DAC and no-DAC are not two versions of one compound

Almost everything written about CJC-1295 dosing fails at the same point: it treats the DAC and no-DAC forms as interchangeable. They are not. CJC-1295 with DAC carries an extra maleimidopropionic acid–lysine unit that binds covalently to serum albumin, and that single modification is the whole difference between a half-life measured in minutes and one measured in days.

The measured human half-life for the DAC form is 5.8 to 8.1 days. The roughly 30 minutes routinely quoted for the no-DAC form, sold as Modified GRF(1-29), has no primary human pharmacokinetic paper behind it that we can find — it is repeated everywhere and sourced nowhere. The molecular weights differ too: 3647.2 Da with DAC, 3367.97 Da without.

The practical consequence is that a dosing frequency copied from one form is meaningless applied to the other, and a vial labelled only CJC-1295 does not tell you which you have. The one published human study used the DAC version.

What the FDA advisory committee actually decided

On 4 December 2024 the Pharmacy Compounding Advisory Committee reviewed CJC-1295 for growth hormone deficiency and voted against adding it to the 503A bulks list, citing lack of evidence of effectiveness. It is worth being precise about what that vote is and is not: it is not a finding that the compound is dangerous, and it is not an approval decision. It is a decision that the evidence does not support compounding pharmacies making it from bulk substance.

It was subsequently removed from Category 2 on 22 April 2026 when the nominations were withdrawn, and it was not among the peptides reconsidered in July 2026. Removal from Category 2 is frequently misreported as promotion to Category 1. It is not. The compound is now on no FDA list at all, which is a weaker position than being on one, not a stronger one.

Common questions

Sources

Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.

RegulatorFDA· 2026-05-14
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
RegulatorFDA· 2024-12-04
PCAC briefing document — substance descriptions and 503A statutory conditions
Published studyJournal of Clinical Endocrinology & Metabolism· 2006
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog
RegulatorWorld Anti-Doping Agency· 2026
WADA 2026 Prohibited List
ReferenceNIH / National Center for Biotechnology Information
PubChem compound records (molecular weights and formulae)
RegulatorFDA
Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
RegulatorFDA
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act